Abstract
Paediatric status epilepticus (SE) is a medical emergency associated with significant morbidity. Benzodiazepines (BZPs) are the current first-line treatment, but do not work in over a third of children presenting with SE. Animal studies have shown that SE can cause changes in synaptic inhibition signalling which can ultimately lead to BZPs becoming ineffective. However, the relevance of these mechanisms in paediatric patients with SE remains unknown. To test this hypothesis, we combine clinical EEG recordings with dynamic causal modelling (DCM). This approach allows model-based inference of cortical synaptic coupling parameters based on EEG recorded across distinct oscillatory states. Our DCM revealed that dynamic changes in inhibitory synaptic coupling explain differences in EEG power spectra associated with BZP-treatment responsiveness, and guide the transition from ictal to interictal state. Furthermore, in silico simulations demonstrate that there are alternative routes to seizure termination even in cortical circuit models unresponsive to the BZPs. Together, our findings confirm that alterations in synaptic inhibition underlie BZP response during paediatric SE. More broadly this work further demonstrates the utility of computational modelling to validate insights from basic science in clinically accessible recordings in neurological disorders characterised by abnormal brain states.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study has received support from the Theodor & Ida Herzog-Egli Foundation Project (R.J.B., G.R., R.E.R.), the Anna Mueller Grocholski Foundation (T.F., R.J.B., G.R., R.E.R.), the Swiss National Science Foundation under grants agreement 208184 (G.R.), the Wellcome Trust (209164/Z/17/Z to R.E.R) and the European Union through the Human Brain Project / SGA3 (R.E.R.).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical oversight was provided by the Cantonal Ethics Commission of Zurich (Kantonale Ethikkommission Zurich) for protocol number KEK-ZH PB-2020-02580. Ethical approval was granted for this study and permission was given to analyse patient data obtained retrospectively. Due to the retrospective nature of the project, the Ethics commission granted a waiver from needing to obtain individual patient consent for routine clinical data to be used in this study.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
Raw EEG data is available upon reasonable request from the corresponding author. The code used to produce the results presented in this manuscript is available on an online repository.
